Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity.

Valeria Castro TejeraLena ÖhmanLars AabakkenBengt FellströmTrygve HauskenØistein HovdeJohann P HreinssonGreger LindbergPer VengeMagnus SimrénHans Törnblom

Published in: Alimentary pharmacology & therapeutics (2022)

Mesalazine is ineffective in reducing IBS symptoms. Rectal measures of immune activity by the mucosal patch technology cannot predict a higher chance of response to mesalazine.

Keyphrases

irritable bowel syndrome
clinical trial
open label
rectal cancer
double blind
study protocol
phase ii
sleep quality
physical activity
ulcerative colitis